Get the Stockscreener App
6.46
1.25%
0.08
After Hours:
6.46
Aquestive Therapeutics Inc stock is traded at $6.46, with a volume of 1.91M.
It is up +1.25% in the last 24 hours and up +4.36% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$6.38
Open:
$6.31
24h Volume:
1.91M
Relative Volume:
0.70
Market Cap:
$788.14M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-17.74
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
+8.21%
1M Performance:
+4.36%
6M Performance:
+95.17%
1Y Performance:
+81.46%
1-Day Range:
$6.23
$6.5669
1-Week Range:
$5.835
$6.5669
52-Week Range:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
6.46 | 778.38M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 5.7%Should You Buy? - MarketBeat
Aquestive Therapeutics, Inc.(NasdaqGM:AQST) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Aquestive Therapeutics (NASDAQ:AQST) shareholders are still up 524% over 3 years despite pulling back 6.6% in the past week - simplywall.st
Is Aquestive Therapeutics Inc. stock gaining market shareWeekly Earnings Recap & Growth Focused Entry Point Reports - Улправда
Is Aquestive Therapeutics Inc. stock a buy on dips2025 Valuation Update & Entry Point Confirmation Signals - Улправда
How rising interest rates impact Aquestive Therapeutics Inc. stock2025 Retail Activity & Long-Term Growth Portfolio Plans - Улправда
Published on: 2025-12-19 18:44:27 - DonanımHaber
How Aquestive Therapeutics Inc. stock benefits from tech adoption2025 Growth vs Value & Accurate Intraday Trade Tips - DonanımHaber
What dividend safety score for Aquestive Therapeutics Inc. stockJuly 2025 News Drivers & Scalable Portfolio Growth Methods - DonanımHaber
Is Aquestive Therapeutics Inc. stock positioned for digital transformation2025 Buyback Activity & Expert Curated Trade Setups - ulpravda.ru
Aquestive Therapeutics Earnings Notes - Trefis
Aquestive Therapeutics (NASDAQ:AQST) Trading Down 4.6%What's Next? - MarketBeat
Is Aquestive Therapeutics Stock Built to Withstand a Pullback? - Trefis
Pale Fire Capital SE Acquires 340,767 Shares of Aquestive Therapeutics, Inc. $AQST - MarketBeat
Looking at the Narrative for Aquestive Therapeutics After New Anaphylm Patents and FDA Momentum - Yahoo Finance
Aquestive Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Published on: 2025-12-08 02:09:31 - BỘ NỘI VỤ
Diametric Capital LP Acquires Shares of 165,373 Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
What analyst consensus says on Aquestive Therapeutics Inc. stockJuly 2025 Intraday Action & Daily Profit Focused Screening - Newser
VP Cioffi Surrenders 2,083 Of Aquestive Therapeutics Inc [AQST] - TradingView
Sio Capital Management LLC Buys 555,860 Shares of Aquestive Therapeutics, Inc. $AQST - MarketBeat
Published on: 2025-12-03 04:52:42 - Newser
Aquestive Therapeutics (AQST) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Everstar Asset Management LLC Raises Holdings in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Quarterly Trades: Why Aquestive Therapeutics Inc. stock could see breakout soon - BỘ NỘI VỤ
Returns Recap: Why Aquestive Therapeutics Inc. stock could see breakout soonPrice Action & Capital Efficiency Focused Ideas - moha.gov.vn
What technical charts say about Aquestive Therapeutics Inc. stockWeekly Investment Summary & Weekly Stock Breakout Alerts - BỘ NỘI VỤ
Aquestive Therapeutics (NASDAQ:AQST) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Aquestive’s Anaphylm Shows Positive Results in First Study in Kids - Allergic Living
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
How Recent Regulatory Wins Are Shaping the Narrative for Aquestive Therapeutics - Yahoo Finance
Aquestive Therapeutics Shares Rise After $75 Million Funding Deal - MSN
Why Aquestive Therapeutics Inc. stock is favored by top institutionsTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
How to monitor Aquestive Therapeutics Inc. with trend dashboardsEarnings Risk Report & High Return Stock Watch Alerts - newser.com
Can Aquestive Therapeutics Inc. stock sustain revenue growthPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Why Aquestive Therapeutics Inc. stock is trending among retail tradersMarket Performance Summary & Proven Capital Preservation Tips - newser.com
Why Aquestive Therapeutics Inc. stock could outperform in 2025July 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
Aquestive Therapeutics (AQST) Price Target Increased by 14.80% to 10.51 - MSN
Aquestive Therapeutics Inc. stock momentum explainedMarket Rally & High Accuracy Trade Signal Alerts - newser.com
Risk vs reward if holding onto Aquestive Therapeutics Inc.Swing Trade & Real-Time Market Sentiment Reports - newser.com
Aquestive Therapeutics (NASDAQ:AQST) Trading Up 6.5%Here's Why - MarketBeat
Officer Kraus Files To Sell 53,100 Of Aquestive Therapeutics Inc [AQST] - TradingView
Will Aquestive Therapeutics Inc. bounce back from current supportLayoff News & AI Based Buy and Sell Signals - newser.com
Can trapped investors hope for a rebound in Aquestive Therapeutics Inc.Analyst Upgrade & Daily Oversold Stock Bounce Ideas - newser.com
Predicting Aquestive Therapeutics Inc. trend using moving averagesJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
Aquestive Therapeutics’ Earnings Call: Optimism Amid Challenges - MSN
Aquestive Therapeutics (NASDAQ:AQST) Updates Amid Dow Jones Industrial Average - Kalkine Media
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.30%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):